Home › Research › Disparities
Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis
Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC.. Archives of neurology, 2011-07-01
Topic: Risk, prevention and care in population studies
Background Antipsychotic (AP) use is common in Parkinson disease (PD), but APs can worsen parkinsonism, evidence for efficacy is limited, and use in patients with dementia increases mortality. Objective To examine the frequency and characteristics, including changes over time, of AP use in a large cohort of patients with PD. Design Using Veterans Affairs data from fiscal year (FY) 2008, rates and predictors of AP prescribing were determined for patients with PD and psychosis stratified by dementia status (N = 2597) and a comparison group of patients with dementia and psychosis without PD (N = 6907). Fiscal year 2008 and FY2002 data were compared to examine changes in AP prescribing over time. Setting Department of Veterans Affairs outpatient facilities. Participants Outpatients with PD and psychosis and outpatients without PD with dementia and psychosis, all receiving care at Veterans Affairs facilities in FY2002 and FY2008. Main outcome measure Antipsychotic prescribing, including overall, class, and specific medications. Results In FY2008, 50% of patients with PD having a diagnosis of psychosis were prescribed an AP. Among treated patients, the atypical AP quetiapine was most frequently prescribed (66%), but approximately 30% received high-potency APs. Clozapine was rarely prescribed ( Conclusions Half of the patients with PD and psychosis receive APs, not uncommonly high-potency agents associated with worsening parkinsonism, and frequency of use has been unchanged since the "black box" warning for AP use in patients with dementia was issued. Recent trends are a shift to quetiapine use and the common use of aripiprazole. As psychosis and dementia are frequently comorbid in PD, safety risks associated with AP use in this population need to be assessed.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Weintraub, D., Chen, P., Ignacio, R. V., Mamikonyan, E., & Kales, H. C. (2011). Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Archives of neurology. https://doi.org/10.1001/archneurol.2011.139
Vancouver
Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Archives of neurology. 2011. doi:10.1001/archneurol.2011.139. PMID: 21747029.
BibTeX
@article{weintraub2011-21747029,
author = {Weintraub, D. and Chen, P. and Ignacio, R. V. and Mamikonyan, E. and Kales, H. C.},
title = {{Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis}},
journal = {Archives of neurology},
year = {2011},
doi = {10.1001/archneurol.2011.139},
pmid = {21747029},
url = {https://doi.org/10.1001/archneurol.2011.139}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Fiscal year 2008 and FY2002 data were compared to examine changes in AP prescribing over time.
- Main outcome measure Antipsychotic prescribing, including overall, class, and specific medications.
- Results In FY2008, 50% of patients with PD having a diagnosis of psychosis were prescribed an AP.
- Clozapine was rarely prescribed ( Conclusions Half of the patients with PD and psychosis receive APs, not uncommonly high-potency agents associated with worsening parkinsonism, and frequency of use has been unchanged since the "black box" warning for AP use in patients with dementia was issued.
- As psychosis and dementia are frequently comorbid in PD, safety risks associated with AP use in this population need to be assessed.
Why it matters
This study examined antipsychotic prescribing patterns for Parkinson disease psychosis, finding that half of such patients received antipsychotics. It is about prescribing practice and does not test any treatment, cure or prevention for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Disparities →
Study details
- Participants2,597
- Evidence strengthModerate
How this study scored 49/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Archives of neurology) |
| Journal's citation record | 3 / 4 | Archives of Neurology: journal h-index 353 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2011 — within 20 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,597 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 109 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.4 citations a year over 17 year(s) since 2011 |
| Impact for its field and year | 3 / 6 | Cited 6.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Daniel A. Weintraub: h-index 115 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Pennsylvania: institution h-index 1,859 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21747029) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/archneurol.2011.139
- PubMed: 21747029
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disparities
Also tagged “bodies”
1,017 studies in the library carry the topic tag “bodies”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.